Can-Fite BioPharma (CANF) announced that a leading group from University of Los Angeles, UCLA, demonstrate that Piclidenoson showed efficacy in an experimental model of vascular dementia. The study headed by Dr. S. Thomas Carmichael, M.D., Ph.D., Professor and Chair Frances Stark Chair, Department of Neurology, Geffen School of Medicine at UCLA, utilized a vascular dementia mouse model with focal ischemia replicating many elements of the complex pathophysiology of human vascular dementia. Piclidenoson was found to restore tissue integrity and behavioral function in this vascular dementia model.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma files to sell 4.9M American depositary shares
- Can-Fite BioPharma’s Shareholders Approve Key Proposals at Annual Meeting
- Can-Fite BioPharma Reschedules Annual Meeting Due to Lack of Quorum
- Can-Fite BioPharma to Present Pancreatic Cancer Study Progress at BIO 2025
- Can-Fite BioPharma to present Phase IIa pancreatic cancer study progress